167 related articles for article (PubMed ID: 17072500)
21. A subclass of soluble HLA-G1 modulates the release of cytokines from mononuclear cells present in the decidua additively to membrane-bound HLA-G1.
Kanai T; Fujii T; Kozuma S; Miki A; Yamashita T; Hyodo H; Unno N; Yoshida S; Taketani Y
J Reprod Immunol; 2003 Dec; 60(2):85-96. PubMed ID: 14638437
[TBL] [Abstract][Full Text] [Related]
22. [HLA-G1 molecule expressed by ECV304 cells inhibit cytotoxic activity of allogeneic NK cells].
Zhang CE; Han JY; Yang HJ; Wu XW; Huang YF; Liang ZH; Gong FL
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Nov; 21(6):676-8. PubMed ID: 16256023
[TBL] [Abstract][Full Text] [Related]
23. Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17.
Agaugué S; Carosella ED; Rouas-Freiss N
Blood; 2011 Jun; 117(26):7021-31. PubMed ID: 21482709
[TBL] [Abstract][Full Text] [Related]
24. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G.
Maki G; Hayes GM; Naji A; Tyler T; Carosella ED; Rouas-Freiss N; Gregory SA
Leukemia; 2008 May; 22(5):998-1006. PubMed ID: 18288133
[TBL] [Abstract][Full Text] [Related]
25. Endoplasmic reticulum aminopeptidase-1 mediates leukemia inhibitory factor-induced cell surface human leukocyte antigen-G expression in JEG-3 choriocarcinoma cells.
Shido F; Ito T; Nomura S; Yamamoto E; Sumigama S; Ino K; Itakura A; Hattori A; Tsujimoto M; Mizutani S; Kikkawa F
Endocrinology; 2006 Apr; 147(4):1780-8. PubMed ID: 16439450
[TBL] [Abstract][Full Text] [Related]
26. Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes.
Baj-Krzyworzeka M; Szatanek R; Weglarczyk K; Baran J; Urbanowicz B; Brański P; Ratajczak MZ; Zembala M
Cancer Immunol Immunother; 2006 Jul; 55(7):808-18. PubMed ID: 16283305
[TBL] [Abstract][Full Text] [Related]
27. The regulation of natural killer-mediated swine endothelial cell lysis by HLA-G (G1 and G3).
Matsunami K; Miyagawa S; Nakai R; Yamada M; Shirakura R
Transplant Proc; 2000 Nov; 32(7):2087-8. PubMed ID: 11120079
[No Abstract] [Full Text] [Related]
28. Cellular co-localization of intron-4 containing mRNA and HLA-G soluble protein in melanoma analyzed by fluorescence in situ hybridization.
Sangrouber D; Marcou C; Le Discorde M; Chang CC; Carosella ED; Moreau P
J Immunol Methods; 2007 Sep; 326(1-2):54-62. PubMed ID: 17689555
[TBL] [Abstract][Full Text] [Related]
29. Cytokine stimulation of the choriocarcinoma cell line JEG-3 leads to alterations in the HLA-G expression profile.
Persson G; Bork JBS; Isgaard C; Larsen TG; Bordoy AM; Bengtsson MS; Hviid TVF
Cell Immunol; 2020 Jun; 352():104110. PubMed ID: 32387976
[TBL] [Abstract][Full Text] [Related]
30. Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms.
Chang CC; Murphy SP; Ferrone S
Hum Immunol; 2003 Nov; 64(11):1057-63. PubMed ID: 14602236
[TBL] [Abstract][Full Text] [Related]
31. Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by gammaIFN treatment.
Frumento G; Franchello S; Palmisano GL; Nicotra MR; Giacomini P; Loke YW; Geraghty DE; Maio M; Manzo C; Natali PG; Ferrara GB
Tissue Antigens; 2000 Jul; 56(1):30-7. PubMed ID: 10958353
[TBL] [Abstract][Full Text] [Related]
32. Effect of proteasome inhibitors on expression of HLA-G isoforms.
Poláková K; Bandzuchová E; Bystrická M; Pancuchárová H; Russ G
Neoplasma; 2006; 53(6):471-7. PubMed ID: 17167714
[TBL] [Abstract][Full Text] [Related]
33. HLA-G gene activation in tumor cells involves cis-acting epigenetic changes.
Mouillot G; Marcou C; Rousseau P; Rouas-Freiss N; Carosella ED; Moreau P
Int J Cancer; 2005 Mar; 113(6):928-36. PubMed ID: 15514928
[TBL] [Abstract][Full Text] [Related]
34. Regulation of classical HLA class I genes in human choriocarcinoma cells by nuclear proteins binding to MHC class I regulatory elements.
Wakimoto A; Ohashi K; Koyama M; Kato M; Tsutsui T; Saji F; Tanizawa O
Am J Reprod Immunol; 1995 Nov; 34(5):323-31. PubMed ID: 8595132
[TBL] [Abstract][Full Text] [Related]
35. HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis.
Riteau B; Rouas-Freiss N; Menier C; Paul P; Dausset J; Carosella ED
J Immunol; 2001 Apr; 166(8):5018-26. PubMed ID: 11290782
[TBL] [Abstract][Full Text] [Related]
36. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape.
Wiendl H; Mitsdoerffer M; Hofmeister V; Wischhusen J; Bornemann A; Meyermann R; Weiss EH; Melms A; Weller M
J Immunol; 2002 May; 168(9):4772-80. PubMed ID: 11971028
[TBL] [Abstract][Full Text] [Related]
37. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells.
Rajagopalan S; Long EO
J Exp Med; 1999 Apr; 189(7):1093-100. PubMed ID: 10190900
[TBL] [Abstract][Full Text] [Related]
38. Choriocarcinoma cell line resistance to NK lysis mainly involves an HLA-G-independent mechanism.
Avril T; Jarousseau AC; Watier H; Bardos P; Thibault G
Transplant Proc; 1999 Jun; 31(4):1866-7. PubMed ID: 10371976
[No Abstract] [Full Text] [Related]
39. Down-regulation of HLA-G boosted natural killer cell-mediated cytolysis in JEG-3 cells cultured in vitro.
Sun LL; Han Y; Chen JH; Yao YQ
Fertil Steril; 2008 Dec; 90(6):2398-405. PubMed ID: 18243178
[TBL] [Abstract][Full Text] [Related]
40. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses.
Rouas-Freiss N; Moreau P; Menier C; LeMaoult J; Carosella ED
Semin Cancer Biol; 2007 Dec; 17(6):413-21. PubMed ID: 17881247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
